Evaluation of Brain Dysfunction in Patients with Duchene Muscular Dystrophy
Study Overview
Status
Conditions
Detailed Description
Duchenne Muscular Dystrophy (DMD) is the second most common inherited genetic disease. It is an X-linked disease that affects approximately one in 3300 live male birth. It is caused by the absence or disruption of the dystrophin protein that is a main component of the dystrophin-glycoprotein complex (DGC). It is found in a variety of tissues, mostly skeletal muscle and neuron cells in specific regions of the CNS ashippocampus, the cerebellum and the neocortex. [1, 2] Clinically DMD is characterized by a severe pathology of the skeletal musculature that results in progressive weakness of muscles including cardiac & respiratory muscles leading to the premature death of the individual.
An important aspect of DMD is the neurocognitive function of patients which, despite its non-progressive nature, still greatly affects the quality of life of the patients and their caregivers.[3]
While not all patients exhibit global cognitive impairments, many do show significant deficits in areas such as arithmetic, verbal fluency, working memory, attention, and executive function. A study by Wingeier et al. (2011) found that boys with DMD scored lower than average on IQ tests, particularly in verbal IQ. Other studies have linked specific cognitive impairments to the absence of certain dystrophin isoforms suggesting a genotype-phenotype correlation between mutation and brain affection, particularly Dp140 and Dp260, which are associated with learning disabilities, ADHD, and autism spectrum disorders (ASD).[1, 3, 4]
Many DMD patients face learning difficulties like those seen in developmental dyslexia, this was attributed to the potential role of cerebellar dysfunction & choline deficit in these cognitive dysfunctions, suggesting that metabolic abnormalities in the cerebellum may contribute to the observed impairments. Overall, the research findings emphasize the need for early intervention and highlight the complex interplay of genetic and non-genetic factors in cognitive function among DMD patients.[5-8]
Neuroimaging studies have revealed structural and functional brain abnormalities, with MR spectroscopy and PET showing metabolic abnormalities. Evidence is also emerging for brain regional volume loss, blood oxygen level-dependent signal abnormalities, and altered WM integrity as measured using Diffusion Tensor Imaging. Furthermore, recent imaging studies have highlighted less severe structural abnormalities in patients with retained Dp140 expression compared with those lacking it.[9-11]
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Aliaa Hassan Ibraheem, Resident doctor
- Phone Number: 01022626306 010-127-521-07
- Email: aliaahassan198@gmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male patients Age children & adolescent (5-18yrs) Patients diagnosed & genetically confirmed DMD, with cross matching of healthy subjects of the same age and number
Exclusion Criteria:
Medical or neurological condition affecting cognition (as endocrinal as Diabetes Mellitus & hypothyroidism, autoimmune disease, history of brain trauma, birth asphyxia, neonatal jaundice, …..) Surgical condition that could potentially impact cognitive function Patients of other types of muscular dystrophy Those who refuse to participate in the study Those with sensory disability (as hearing loss, blindness, severe speech delay) Those with non-invasive or invasive ventilation support with inability to speak and answer oral questions
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Screening for early detection and management
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Brain evaluation in duchenne
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.